APA (7th ed.) Citation

Hetta, H. F., Salama, A., Aljuaid, T. A., Mojmami, Y. T., Alotibi, R. S., Alqabaly, A. M., . . . Sayad, R. (2026). Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. Pharmaceuticals (14248247), 19(3), 467. https://doi.org/10.3390/ph19030467

Chicago Style (17th ed.) Citation

Hetta, Helal F., et al. "Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis." Pharmaceuticals (14248247) 19, no. 3 (2026): 467. https://doi.org/10.3390/ph19030467.

MLA (9th ed.) Citation

Hetta, Helal F., et al. "Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis." Pharmaceuticals (14248247), vol. 19, no. 3, 2026, p. 467, https://doi.org/10.3390/ph19030467.